SURMOUNT-1 demonstrated that tirzepatide, a dual GIP/GLP-1 receptor agonist, produces dose-dependent mean weight reductions of 15.0–20.9% in adults with obesity without type 2 diabetes, with 57% of participants at the 15 mg dose losing 20% or more of body weight, setting a new pharmacological efficacy benchmark comparable in magnitude to bariatric surgery outcomes.
Browsing: Metabolism
Obesity and weight management, metabolic syndrome and insulin resistance, MASLD/fatty liver, and nutrition and lifestyle evidence.
STEP 1 demonstrated that once-weekly semaglutide 2.4 mg produced a mean weight reduction of 14.9% compared with 2.4% with placebo in adults with obesity without type 2 diabetes, with a third of participants losing more than 20% of body weight, setting a new benchmark for pharmacological weight management and preceding the cardiovascular outcomes evidence from SELECT.
A four-arm RCT finds combining training with a polyphenol supplement improves prediabetes markers most, with exercise the main driver. PICO summary and expert commentary.
An RCT finds the AntiAGE-Biom probiotic does not lower HbA1c but shows a subgroup body-composition signal in type 2 diabetes. PICO summary and expert commentary.
An RCT finds Chester Step Test-guided post-dinner exercise lowers postprandial glucose and variability in type 2 diabetes on exercise days. PICO summary and expert commentary.
An RCT finds driving pressure-guided ventilation improves oxygenation and cuts intraoperative hypoxia in bariatric surgery, on physiological endpoints. PICO summary and commentary.
A recruitment analysis finds men, Hispanics, and Spanish speakers underenrol at every step of a diabetes exercise trial despite active outreach. PICO summary and commentary.
A small unblinded trial finds Huayu Tongluo moxibustion improves cognition and insulin resistance in type 2 diabetes, with high placebo potential. PICO summary and commentary.
A clamp-based RCT finds metformin does not reduce hepatic insulin resistance in type 1 diabetes, arguing against its use as an insulin-sensitiser. PICO summary and commentary.
A secondary analysis finds beetroot supplements improve fatty acid and oxidant markers in coronary artery disease, but only short-term surrogates. PICO summary and commentary.